Vactosertib is under clinical development by MedPacto and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vactosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vactosertib overview

Vactosertib (TEW-7197) is under development for the treatment of advanced solid tumors including melanoma, breast cancer, hepatocellular carcinoma, metastatic non-small cell lung cancer, prostate cancer, chronic myelocytic leukemia, myelodysplastic syndrome, metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, adenocarcinoma of the gastroesophageal junction, esophageal adenocarcinoma, glioblastoma multiforme, gastric cancer, pancreatic cancer, desmoid sarcoma, metastatic urothelial bladder carcinoma including renal pelvis cancer, ureters cancer, urinary bladder cancer, refractory acute myeloid leukemia, relapsed acute myeloid leukemia, acute lymphoblastic lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma and urethral cancer, myeloproliferative neoplasm, colon cancer and inflammatory bowel disease. The drug candidate is administered orally as a tablet. It acts by inhibiting protein serine/threonine kinase activity of transforming growth factor (TGF)-beta receptor type 1 (TGFBR1, ALK5). It was also under development for refractory and relapsed multiple myeloma, hepatic fibrosis, renal fibrosis, pulmonary fibrosis.

MedPacto overview

MedPacto, a subsidiary of Theragen Etex Co Ltd, is a biotechnology company that discovers and develops therapies to treat cancer and autoimmune diseases. Its product pipeline comprise Vactosertib drug, to treat gastric and pancreatic cancer, desmoid sarcoma, colorectal and bladder cancer, non-small cell lung carcinoma (NSCLC), multiple myeloma and myeloproliferative neoplasms. The company is also investigating MA-B2, MPD-001, MPD-002 and MPD-003 against solid tumors; MU-D201, to treat diffuse large B-cell lymphoma (DLBCL); and also MI-S4 for nonalcoholic steatohepatitis (NASH). It works in partnership with pharmaceutical companies including Merck and AstraZeneca Plc. MedPacto is headquartered in Seoul, South Korea.

For a complete picture of Vactosertib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.